KRAS protein inhibitor - FogPharma
Alternative Names: Pan-KRAS protein inhibitor - FogPharma; Pan-RAS - FogPharma; PanKRAS (ON) - FogPharmaLatest Information Update: 30 Dec 2022
At a glance
- Originator FogPharma
- Class Antineoplastics; Peptides
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 13 Dec 2022 Early research in Cancer in USA (unspecified route) (FogPharm pipeline, December 2022)
- 31 Dec 2017 Harvard university licenses Helicon™ peptides technology to FogPharma prior to December 2017 (FogPharma website, March 2021)